Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Why clinicians are the critical link for AI in transforming oncology care

By Brian Buntz | January 25, 2024

Young female clinician showing medical documents to experienced male doctor sitting by table in front of group of intercultural colleagues

[Adobe Stock]

In the third episode of AI Meets Life Sci, Ben Newton, General Manager of Oncology at GE Healthcare, offered a succinct definition of artificial intelligence that harkens back to the original conception from the 1950s, when researchers gathered at Dartmouth College to lay the groundwork for the field. “AI for me is the simulation of human intelligence by machines, essentially, or computer systems,” Newton said.

Harnessing the power of machine intelligence is increasingly a priority owing to the surging volumes of data in the field. Contributing to the trend are advances in radiological imaging, genomics as well as the continued evolution of electronic health records and personalized medicine. The healthcare industry is emerging as one of the biggest producers of data with RBC Capital Markets estimating that the sector now produces roughly 30% of the world’s data volume. RBC projects that the compound annual growth rate of data for healthcare will hit 36% by 2025 — significantly faster than in manufacturing, financial services, and media and entertainment.

Taming the healthcare data deluge

Ben Newton

Ben Newton

Amidst this data deluge, the promise of AI in healthcare is more of a complement to human intelligence than a replacement for human expertise. In the recent past, some radiologists, for instance, worried about the prospect of full automation of image reading. “I think what’s very clear is, that’s not going to happen,” he said. Instead, technologies such as deep learning and machine learning algorithms have optimized the speed and accuracy of image analysis, accelerating the volume of reads without compromising quality. “What is going to happen is AI can be used in a way that will support radiologists to do a higher volume of reads,” Newton said.

Similarly, Haley Schwartz, CEO at Catalyze Healthcare, noted in the episode, and here as well, that not only is data volume in the field accelerating, but the quality of the data is emerging as a growing priority as well. “It’s really about quality of data and not just volume of data,” she summarized. The power of compute and quality of algorithms are also steadily improving, paving the way for AI systems that not just aid in screening but also support diagnostic and therapeutic applications.

 

Unlocking the power of multimodal AI requires a strategic approach

Haley Schwartz

Haley Schwartz

The field stands to advance further with the advent of multimodal computing. Traditionally, many AI systems in healthcare have focused on data in discrete, unimodal environments such as in imaging. But now, it is growing more common to link data from sources spanning domains spanning demographics, pathology, imaging, and genomics. This connecting of the dots can lead to improved predictive power as well as improved quality of decision-making for patient care.

The implementation of AI in healthcare is perhaps uniquely challenging, however, in several respects. Hurdles to navigate include patient security, ensuring data integrity, ensuring AI systems can adapt to the nuances of human workflows. But as AI systems become more increasingly integrated into clinical workflows, the synthesis of human expertise and machine intelligence is poised to become ever-more synergistic.

Again, here multimodal data promises to be transformative, leading Newton to envision a future where AI not only aids in the present diagnosis but also augments the prognostic capabilities of healthcare professionals. Bridging imaging data with other sources could lead to systems that are increasingly predictive. Such a transition would represent a 180 degree shift away from “what has happened” to a more forward-looking approach, where the focus is on predicting ‘what may happen,” Newton said. “That prognostic power is huge,” he added, highlighting its role in determining the most effective treatment strategies. Given the possibilities, radiologists have reason for optimism given their involvement as diagnosticians.

AI takes a village

Achieving such outcomes, however, will take close collaboration across the industry with Big Tech companies also playing a role. “It will take a village,” Newton said, highlighting the need for working with cloud partners, academic centers, and data scientists to create the foundation models that will translate AI visions for AI systems into tangible improvements in patient outcomes and healthcare professional workflows.

Recognizing that it takes a village, clinicians will play a critical role in ensuring the successful adoption of AI in healthcare. As Schwartz emphasized, physician involvement is essential for building trust in AI systems and effectively integrating them into clinical workflows, especially for high-acuity patients. Clinicians need to be present at the bedside as AI algorithms “practice under their licenses.” Ultimately, it’s a human in the loop that must retain responsibility and accountability for patient care decisions and outcomes. “I think that’s one big piece,” Schwartz concluded.


Filed Under: Oncology
Tagged With: AI Healthcare Applications, AI in Patient Care, Data Management in Healthcare, Diagnostic AI Technologies, electronic health records, Multimodal AI Computing, Radiological Imaging AI
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

AP Biosciences charts course for safer CD137 bispecifics with its T-cube platform
Cellares and UW-Madison partner to automate manufacturing for novel solid tumor CAR-T
Why smaller, simpler molecular glues are gaining attention in drug discovery
Technology background. Big data concept. Binary computer code. Vector illustration.
COTA Healthcare announces AI milestone in real-world oncology data
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE